Image Sativex achieved sustained improvements in spasticity vs placebo when used as an adjunct1 Response rates Image Up to 71% of patients responded to 4 weeks’ treatment with Sativex*1–4 The response rates achieved in practice were at least as good as those seen in clinical trials*1–4 Image Image Learn about the 4-week trial period and GW Pharmaceuticals’ pay-for-responders scheme *A response was defined as a ≥20% improvement in spasticity-related symptoms over 4 weeks using a 0–10 patient-reported NRS. NRS, numerical rating scale. References:1. Novotna A et al. Eur J Neurol 2011; 18: 1122–1131.2. Markovà J et al. Int J Neurosci 2019; 129: 119–128.3. Patti F. Eur Neurol 2016; 75 Suppl 1: 9–12.4. Patti F et al. Neurol Sci 2020; 41: 2905–2913.